List of Biologic & Biosimilar Drugs
Click on the names below to read more about each medication.
List of Biologics and Biosimilars (Psoriasis)
IL12/23 Blockers
IL36 Blocker (generalized pustular psoriasis flares)
List of Biologics and Biosimilars (Psoriatic Arthritis)
IL17 Blockers
IL12/23 Blockers
Abatacept
Etanercept (TNF Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Etanercept is a biologic that targets the overactive immune system in psoriasis. Etanercept works by supressing tumor necrosis factor-alpha (TNFa). Useful in psoriasis and psoriatic arthritis.
How Is It Used?
Etanercept is an injectable medication that is administered subcutaneously. This can be home dosed.
For plaque psoriasis:
50 mg twice weekly for 3 months, then 50 mg once weekly thereafter
For psoriatic arthritis:
50 mg once weekly
What Are The Possible Side Effects?
The most common side effects of etanercept include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of etanercept, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on etanercept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on etanercept.
Etanercept and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Etanercept should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Etanercept should be avoided in patients who are immunocompromised or HIV positive.
What Medications Interact With This Treatment?
Some medications that may interact with etanercept include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with etanercept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – S/A | Yes – S/A | NA | https://pdf.hres.ca/dpd_pm/00065129.PDF | March 17, 2022 |
Alberta | Biologics and Biosimilars | Etanercept | Enbrel® | Yes - pediatric patients weighing less than 63 kg | No | https://pdf.hres.ca/dpd_pm/00048003.PDF | https://pdf.hres.ca/dpd_pm/00060454.PDF | March 19, 2021 |
Alberta | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00049267.PDF | https://pdf.hres.ca/dpd_pm/00069556.PDF | Jan 18, 2023 |
British Columbia | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - S/A | Yes – S/A | |||
British Columbia | Biologics and Biosimilars | Etanercept | Enbrel® | No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | |||
British Columbia | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - S/A | Yes – S/A | |||
Manitoba | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - EDS | Yes - EDS | |||
Manitoba | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis. | Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis. | |||
Manitoba | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – EDS | Yes – EDS | |||
New Brunswick | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - S/A | Yes - S/A | |||
New Brunswick | Biologics and Biosimilars | Etanercept | Enbrel® | No All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021. | No. All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021. | |||
New Brunswick | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Brenzys® | No | No | |||
Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Enbrel® | Yes–S/A All new requests for coverage of etanercept received after March 1, 2018 will be approved for the biosimilar version only. | Yes–S/A All new requests for coverage of etanercept received after March 1, 2018 will be approved for the biosimilar version only. | |||
Newfoundland and Labrador | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A | |||
NIHB | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – L/U (may vary by province) | Yes – L/U (may vary by province/territory) | |||
NIHB | Biologics and Biosimilars | Etanercept | Enbrel® | No | Yes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars. | |||
NIHB | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - L/U | Yes- L/U | |||
Northwest Territories | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – L/U (may vary by province) | Yes – L/U (may vary by province/territory) | |||
Northwest Territories | Biologics and Biosimilars | Etanercept | Enbrel® | No | Yes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars. | |||
Northwest Territories | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - L/U | Yes- L/U | |||
Nova Scotia | Biologics and Biosimilars | Etanercept | Brenzys® | Yes - EDS | Yes - EDS | |||
Nova Scotia | Biologics and Biosimilars | Etanercept | Enbrel® | No - barring exception | No - barring exception | |||
Nova Scotia | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - EDS | Yes – EDS | |||
Nunavut | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – L/U (may vary by province) | Yes – L/U (may vary by province/territory) | |||
Nunavut | Biologics and Biosimilars | Etanercept | Enbrel® | No | Yes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars. | |||
Nunavut | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - L/U | Yes- L/U | |||
Ontario | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – L/U | Yes – L/U | |||
Ontario | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – L/U | No | |||
Ontario | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – L/U | Yes – L/U | |||
Prince Edward Island | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes-S/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – S/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Etanercept | Enbrel® | Yes – S/A. If treatment and reimbursement began before August 19 2020. | Yes – S/A. If treatment and reimbursement began before August 19 2020. | |||
Quebec | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – S/A | Yes – S/A | |||
Saskatchewan | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – EDS | Yes – EDS | |||
Saskatchewan | Biologics and Biosimilars | Etanercept | Enbrel® | No. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation | No. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation | |||
Saskatchewan | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes – EDS | Yes – EDS | |||
Yukon | Biologics and Biosimilars | Etanercept | Brenzys® | Yes – L/U (may vary by province) | Yes – L/U (may vary by province/territory) | |||
Yukon | Biologics and Biosimilars | Etanercept | Enbrel® | No | Yes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars. | |||
Yukon | Biologics and Biosimilars | Etanercept | Erelzi™ | Yes - L/U | Yes- L/U |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
Enbrel®: https://pdf.hres.ca/dpd_pm/00048003.PDF
Erelzi™: https://pdf.hres.ca/dpd_pm/00049267.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Etanercept (Enbrel®): https://www.amgen.ca/products/patient-assistance/
Etanercept biosimilar (Erelzi™): Call 1-844-27XPOSE (1-844-279-7673) for information
Brenzys
Harmony patient support program
Phone 1-866-556-5663
https://rheuminfo.com/docs/physician-tools/patient-support-programs/Brenzys_EN.pdf
Adalimumab (TNF Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Adalimumab is a biologic that targets the overactive immune system in psoriasis. Adalimumab works by supressing tumor necrosis factor (TNFa). Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Adalimumab is an injectable medication that is administered subcutaneously. This can be home dosed.
For plaque psoriasis:
80 mg as an initial dose, then 40 mg every other week starting one week after initial dose
For psoriatic arthritis:
40 mg every other week
What Are The Possible Side Effects?
The most common side effects of adalimumab include temporary pain and redness around the injection site, headaches, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of adalimumab, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on adalimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on adalimumab.
Adalimumab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Adalimumab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
What Medications Interact With This Treatment?
Some medications that may interact with adalimumab include abatacept (Orencia®), anakinra (Kineret®) and other TNF-blockers such as Enbrel®, Remicade®, Cimzia®, or Simponi®. Adalimumab can potentially affect the speed at which cyclosporine and warfarin are metabolized and their doses may need to be adjusted. For a complete list of medications that may interact with adalimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - S/A | Yes - S/A | https://pdf.hres.ca/dpd_pm/00068228.PDF | Nov 14, 2022 | |
Alberta | Biologics and Biosimilars | Adalimumab | Amgevita® | No | No | NA | https://pdf.hres.ca/dpd_pm/00067468.PDF | 9 September, 2022 |
Alberta | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00068763.PDF | Dec 14, 2022 |
Alberta | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00068848.PDF | December 22, 2022 |
Alberta | Biologics and Biosimilars | Adalimumab | Humira® | No | No | https://pdf.hres.ca/dpd_pm/00052133.PDF | https://pdf.hres.ca/dpd_pm/00068848.PDF | December 22, 2022 |
Alberta | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00067757.PDF | October 11, 2022 |
Alberta | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00058541.PDF | October 30, 2020 |
Alberta | Biologics and Biosimilars | Adalimumab | SIMLANDI™ | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00068814.PDF | Dec 9, 2022 |
Alberta | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - S/A | Yes - S/A | NA | https://pdf.hres.ca/dpd_pm/00069429.PDF | February 3, 2023 |
British Columbia | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - S/A | Yes - S/A | |||
British Columbia | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A | |||
British Columbia | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A | |||
British Columbia | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A | |||
British Columbia | Biologics and Biosimilars | Adalimumab | Humira® | No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | |||
British Columbia | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A | |||
British Columbia | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A | |||
British Columbia | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - S/A | Yes - S/A | |||
British Columbia | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - S/A | Yes - S/A | |||
Manitoba | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - EDS | Yes - EDS | |||
Manitoba | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - EDS | Yes - EDS | |||
Manitoba | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - EDS | Yes - EDS | |||
Manitoba | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - EDS | Yes - EDS | |||
Manitoba | Biologics and Biosimilars | Adalimumab | Humira® | No | No | |||
Manitoba | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - EDS | Yes - EDS | |||
Manitoba | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - EDS | Yes - EDS | |||
Manitoba | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - EDS | Yes - EDS | |||
Manitoba | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - EDS | Yes - EDS | |||
New Brunswick | Biologics and Biosimilars | Adalimumab | Abrilada® | No | No | |||
New Brunswick | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A | |||
New Brunswick | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A | |||
New Brunswick | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A | |||
New Brunswick | Biologics and Biosimilars | Adalimumab | Humira® | No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021. | No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021. | |||
New Brunswick | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A | |||
New Brunswick | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A | |||
New Brunswick | Biologics and Biosimilars | Adalimumab | SIMLANDI | No | No | |||
New Brunswick | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - S/A | Yes - S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - S/A | Yes - S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - S/A | Yes - S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - S/A | Yes - S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Humira® | Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira. | Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira. | |||
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - S/A | Yes - S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - S/A | Yes - SA | |||
Newfoundland and Labrador | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - S/A | Yes - SA | |||
NIHB | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - L/U | Yes - L/U | |||
NIHB | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U | |||
NIHB | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U | |||
NIHB | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U | |||
NIHB | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | |||
NIHB | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U | |||
NIHB | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U | |||
NIHB | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - L/U | Yes - L/U | |||
NIHB | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | |||
Northwest Territories | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - L/U | Yes - L/U | |||
Nova Scotia | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - EDS | Yes - EDS | |||
Nova Scotia | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - EDS | Yes - EDS | |||
Nova Scotia | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - EDS | Yes - EDS | |||
Nova Scotia | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - EDS | Yes - EDS | |||
Nova Scotia | Biologics and Biosimilars | Adalimumab | Humira® | No - barring exception | No - barring exception | |||
Nova Scotia | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - EDS | Yes - EDS | |||
Nova Scotia | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - EDS | Yes - EDS | |||
Nova Scotia | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - EDS | Yes - EDS | |||
Nova Scotia | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - EDS | Yes - EDS | |||
Nunavut | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - L/U | Yes - L/U | |||
Nunavut | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U | |||
Nunavut | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U | |||
Nunavut | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U | |||
Nunavut | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | |||
Nunavut | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U | |||
Nunavut | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U | |||
Nunavut | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - L/U | Yes - L/U | |||
Nunavut | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - L/U | Yes - L/U | |||
Ontario | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - L/U | Yes - L/U | NA | https://pdf.hres.ca/dpd_pm/00068228.PDF | Nov 14, 2022 |
Ontario | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U | |||
Ontario | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U | |||
Ontario | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U | |||
Ontario | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U | No | |||
Ontario | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U | |||
Ontario | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U | |||
Ontario | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - L/U | Yes - L/U | |||
Ontario | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - L/U | Yes - L/U | |||
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Hulio® | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Humira® | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - S/A | Yes - S/A | |||
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Idacio® | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes – S/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes – S/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes – S/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - S/A | Yes - S/A | |||
Quebec | Biologics and Biosimilars | Adalimumab | Hulio® | Yes – S/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Adalimumab | Humira® | Yes - S/A. If treatment and reimbursement began before March 3 2021. | Yes - S/A. If treatment and reimbursement began before March 3 2021. | |||
Quebec | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes – S/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Adalimumab | Idacio® | Yes – S/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes – S/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes – S/A | Yes – S/A | |||
Saskatchewan | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes – EDS | Yes – EDS | |||
Saskatchewan | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes – EDS | Yes – EDS | |||
Saskatchewan | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes – EDS | Yes – EDS | |||
Saskatchewan | Biologics and Biosimilars | Adalimumab | Hulio® | Yes – EDS | Yes – EDS | |||
Saskatchewan | Biologics and Biosimilars | Adalimumab | Humira® | No | No | |||
Saskatchewan | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes – EDS | Yes – EDS | |||
Saskatchewan | Biologics and Biosimilars | Adalimumab | Idacio® | Yes – EDS | Yes – EDS | |||
Saskatchewan | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - EDS | Yes - EDS | |||
Saskatchewan | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - EDS | Yes - EDS | |||
Yukon | Biologics and Biosimilars | Adalimumab | Abrilada® | Yes - L/U | Yes - L/U | |||
Yukon | Biologics and Biosimilars | Adalimumab | Amgevita® | Yes - L/U | Yes - L/U | |||
Yukon | Biologics and Biosimilars | Adalimumab | Hadlima® | Yes - L/U | Yes - L/U | |||
Yukon | Biologics and Biosimilars | Adalimumab | Hulio® | Yes - L/U | Yes - L/U | |||
Yukon | Biologics and Biosimilars | Adalimumab | Humira® | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars. | |||
Yukon | Biologics and Biosimilars | Adalimumab | Hyrimoz® | Yes - L/U | Yes - L/U | |||
Yukon | Biologics and Biosimilars | Adalimumab | Idacio® | Yes - L/U | Yes - L/U | |||
Yukon | Biologics and Biosimilars | Adalimumab | SIMLANDI | Yes - L/U | Yes - L/U | |||
Yukon | Biologics and Biosimilars | Adalimumab | Yuflyma® | Yes - L/U | Yes - L/U |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00052133.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
AbbVie Care Support Program
https://abbviecare.ca/
Hadlima
Phone 1-866-556-5663 | https://harmonyorganon.ca/hadlima/en/index.html
Hyrimoz
Phone 1-888-6-SANDOZ (726369) | Email support.continum@sandoz.com
Idacio
Idacio KabiCare patient support program
https://kabicare.ca | Phone 1-888-304-2034| Email info@kabicare.ca
Amgevita
Enliven Services:
Phone: 1-877-936-2735 | Email amgevita@oneenliven.ca
www.amgevita.ca
Hulio
hulio.ca
Phone: 1-844-485-4677 | Email hulio@assistprogram.com
Infliximab (TNF Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Infliximab is a biologic that targets the overactive immune system in psoriasis. Infliximab works by supressing tumor necrosis factor-alpha (TNFa). Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Infliximab is an injectable medication that is administered intravenously, useful for psoriasis and psoriatic arthritis. Typically this is done in an infusion centre.
For plaque psoriasis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter
For psoriatic arthritis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.
What Are The Possible Side Effects?
The most common side effects of infliximab include temporary pain and redness around the infusion site, headaches, nausea, joint pain, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of infliximab, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on infliximab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on infliximab.
Infliximab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Infliximab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
What Medications Interact With This Treatment?
Some medications that may interact with infliximab include cyclosporine, echinacea, phenytoin, and warfarin. For a complete list of medications that may interact with infliximab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Infliximab | Avsola® | Yes – S/A | Yes – S/A | NA | https://pdf.hres.ca/dpd_pm/00065940.PDF | May 17, 2022 |
Alberta | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | https://pdf.hres.ca/dpd_pm/00059824.PDF | ||
Alberta | Biologics and Biosimilars | Infliximab | Remicade® | No | No | https://pdf.hres.ca/dpd_pm/00047753.PDF | https://pdf.hres.ca/dpd_pm/00067676.PDF | Oct 07, 2022 |
Alberta | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00050544.PDF | https://pdf.hres.ca/dpd_pm/00069528.PDF | Feb 09, 2023 |
Alberta | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00047053.PDF | https://pdf.hres.ca/dpd_pm/00057004.PDF | |
Alberta | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | https://pdf.hres.ca/dpd_pm/00068865.PDF | ||
British Columbia | Biologics and Biosimilars | Infliximab | Avsola® | Yes – S/A | Yes – S/A | |||
British Columbia | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - S/A | Yes - S/A | |||
British Columbia | Biologics and Biosimilars | Infliximab | Remicade® | No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis. | |||
British Columbia | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A | |||
British Columbia | Biologics and Biosimilars | Infliximab | Remsima® | No | No | |||
British Columbia | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
Manitoba | Biologics and Biosimilars | Infliximab | Avsola® | Yes - EDS | Yes - EDS | |||
Manitoba | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – EDS | Yes – EDS | |||
Manitoba | Biologics and Biosimilars | Infliximab | Remicade® | Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product. | Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product. | |||
Manitoba | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – EDS | Yes – EDS | |||
Manitoba | Biologics and Biosimilars | Infliximab | Remsima® | No | No | |||
Manitoba | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
New Brunswick | Biologics and Biosimilars | Infliximab | Avsola® | Yes - S/A | Yes - S/A | |||
New Brunswick | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - S/A | Yes - S/A | |||
New Brunswick | Biologics and Biosimilars | Infliximab | Remicade® | No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021. | No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021. | |||
New Brunswick | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - S/A | Yes - S/A | |||
New Brunswick | Biologics and Biosimilars | Infliximab | Remsima® | Non | Non | |||
New Brunswick | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Avsola® | Yes - S/A | Yes - SA | |||
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – S/A | Yes – S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Remicade® | Yes – S/A; : Inflectra, Renflexis or Avsola are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). | No | |||
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
Newfoundland and Labrador | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
NIHB | Biologics and Biosimilars | Infliximab | Avsola® | Yes - L/U | Yes - L/U | |||
NIHB | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - L/U | Yes - L/U | |||
NIHB | Biologics and Biosimilars | Infliximab | Remicade® | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | |||
NIHB | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U | |||
NIHB | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
NIHB | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
Northwest Territories | Biologics and Biosimilars | Infliximab | Avsola® | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Infliximab | Remicade® | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | |||
Northwest Territories | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
Northwest Territories | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
Nova Scotia | Biologics and Biosimilars | Infliximab | Avsola® | Yes – EDS | Yes – EDS | |||
Nova Scotia | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – EDS | Yes – EDS | |||
Nova Scotia | Biologics and Biosimilars | Infliximab | Remicade® | No - barring exception | No - barring exception | |||
Nova Scotia | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – EDS | Yes – EDS | |||
Nova Scotia | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
Nova Scotia | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
Nunavut | Biologics and Biosimilars | Infliximab | Avsola® | Yes - L/U | Yes - L/U | |||
Nunavut | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - L/U | Yes - L/U | |||
Nunavut | Biologics and Biosimilars | Infliximab | Remicade® | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | |||
Nunavut | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U | |||
Nunavut | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
Nunavut | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
Ontario | Biologics and Biosimilars | Infliximab | Avsola® | Yes – L/U | Yes – L/U | |||
Ontario | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – L/U | Yes – L/U | |||
Ontario | Biologics and Biosimilars | Infliximab | Remicade® | No | No | |||
Ontario | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – L/U | Yes – L/U | |||
Ontario | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
Ontario | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
Prince Edward Island | Biologics and Biosimilars | Infliximab | Avsola® | No | No | |||
Prince Edward Island | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Infliximab | Remicade® | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – S/A | Yes – S/A | |||
Prince Edward Island | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
Prince Edward Island | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
Quebec | Biologics and Biosimilars | Infliximab | Avsola® | Yes - S/A | Yes - S/A | |||
Quebec | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - S/A | Yes - S/A | |||
Quebec | Biologics and Biosimilars | Infliximab | Remicade® | Yes – S/A. If treatment and reimburesement began before August 19, 2020 | Yes – S/A. If treatment and reimburesment began before August 19, 2020 | |||
Quebec | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - S/A | Yes - S/A | |||
Quebec | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
Quebec | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
Saskatchewan | Biologics and Biosimilars | Infliximab | Avsola® | Yes – EDS | Yes – EDS | |||
Saskatchewan | Biologics and Biosimilars | Infliximab | Inflectra® | Yes – EDS | Yes – EDS | |||
Saskatchewan | Biologics and Biosimilars | Infliximab | Remicade® | No | No | |||
Saskatchewan | Biologics and Biosimilars | Infliximab | Renflexis® | Yes – EDS | Yes – EDS | |||
Saskatchewan | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
Saskatchewan | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No | |||
Yukon | Biologics and Biosimilars | Infliximab | Avsola® | Yes - L/U | Yes - L/U | |||
Yukon | Biologics and Biosimilars | Infliximab | Inflectra® | Yes - L/U | Yes - L/U | |||
Yukon | Biologics and Biosimilars | Infliximab | Remicade® | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.) | |||
Yukon | Biologics and Biosimilars | Infliximab | Renflexis® | Yes - L/U | Yes - L/U | |||
Yukon | Biologics and Biosimilars | Infliximab | Remsima™ | No | No | |||
Yukon | Biologics and Biosimilars | Infliximab | Omvyence™ | No | No |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
Remicade®: https://pdf.hres.ca/dpd_pm/00047753.PDF
Inflectra®: https://pdf.hres.ca/dpd_pm/00047053.PDF
Renflexis®: https://pdf.hres.ca/dpd_pm/00050544.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Infliximab (Remicade®): https://www.bioadvancemember.ca/en/global/home
Infliximab biosimilar Inflectra®: https://www.pfizer.ca/assistance-programs
Infliximab biosimilar Renflexis®: http://www.merckharmony.ca/
Avsola
Enliven Services
Ph: 1-877-9ENBREL (936-2735) | Email info@oneenliven.ca
www.enbrel.ca; www.avsola.ca
Remsima
CELLTRION CONNECT™ patient support program for Remsima
Interested individuals can find out more about CELLTRION CONNECT™ by visiting www.celltrionconnect.ca/
Certolizumab pegol (TNF Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Certolizumab is a biologic that targets the overactive immune system in psoriasis. Certolizumab works by supressing tumor necrosis factor-alpha (TNFa).
Useful in psoriasis and psoriatic arthritis.
How Is It Used?
Certolizumab is an injectable medication that is administered subcutaneously.
For plaque psoriasis:
400 mg every 2 weeks
For psoriatic arthritis:
400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks
What Are The Possible Side Effects?
The most common side effects of certolizumab include joint pain, and an increased risk of upper respiratory tract infections and urinary tract infections. To obtain a comprehensive list of all known potential side effects of certolizumab, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on certolizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on certolizumab.
Certolizumab should be avoided in patients with moderate to severe heart failure.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
What Medications Interact With This Treatment?
Some medications that may interact with certolizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with certolizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | https://pdf.hres.ca/dpd_pm/00049574.PDF | https://pdf.hres.ca/dpd_pm/00053920.PDF | November 13, 2019 |
British Columbia | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | N/A | Yes - S/A | |||
Manitoba | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS | |||
New Brunswick | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | Yes – S/A | ||||
Newfoundland and Labrador | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – S/A | |||
NIHB | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes - L/U | |||
Nova Scotia | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | Yes - EDS | Yes - EDS | |||
Nunavut | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes - L/U | |||
Ontario | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | No | |||
Prince Edward Island | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes | |||
Quebec | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | Yes – S/A | Yes – S/A | |||
Saskatchewan | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes – EDS | |||
Yukon | Biologics and Biosimilars | Certolizumab pegol | Cimzia® | No | Yes - L/U |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00049574.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Golimumab (TNF Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Golimumab is a biologic that targets the overactive immune system in psoriatic arthritis. Golimumab works by supressing tumor necrosis factor-alpha (TNFa).
How Is It Used?
Golimumab is a biologic medication that can be administered either subcutaneously or intravenously.
What Are The Possible Side Effects?
The most common side effects of golimumab are an increased risk of infection and a temporary injection site reaction. To obtain a comprehensive list of all known potential side effects of golimumab, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on golimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on golimumab.
Golimumab should be avoided in patients with severe heart failure.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
What Medications Interact With This Treatment?
Some medications that may interact with golimumab include abatacept, anakinra, baricitinib, belimumab, canakizumab, certolizumab pegol, cladribine, echinacea, infliximab, leflunomide, natalizumab, pimecrolimus, rilonacept, roflumilast, tacrolimus, tocilizumab, tofacitinib, and vedolizumab. For a complete list of medications that may interact with golimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00051840.PDF | https://pdf.hres.ca/dpd_pm/00067454.PDF | September 9, 2022 |
British Columbia | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | |||
Manitoba | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – EDS | |||
New Brunswick | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | |||
NIHB | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | |||
Northwest Territories | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | |||
Nova Scotia | Biologics and Biosimilars | Golimumab | Simponi® | No | Yes – EDS | |||
Nunavut | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U | |||
Ontario | Biologics and Biosimilars | Golimumab | Simponi® | N/A | No | |||
Prince Edward Island | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – S/A | |||
Saskatchewan | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – EDS | |||
Yukon | Biologics and Biosimilars | Golimumab | Simponi® | N/A | Yes – L/U |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00051840.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Ixekizumab (IL17 Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Ixekizumab is a biologic that targets the overactive immune system in psoriasis. Ixekizumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Ixekizumab is an injectable medication that is administered subcutaneously.
For plaque psoriasis:
160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12, and then 80 mg every 4 weeks
For psoriatic arthritis:
160 mg once, followed by 80 mg every 4 weeks
What Are The Possible Side Effects?
The most common side effects of ixekizumab include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ixekizumab, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on ixekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ixekizumab.
Ixekizumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
What Medications Interact With This Treatment?
Some medications that may interact with ixekizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ixekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00069828.PDF | ||
British Columbia | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A | |||
Manitoba | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – EDS | Yes – EDS | |||
New Brunswick | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A | |||
NIHB | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | Yes – L/U | |||
Northwest Territories | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | Yes – L/U | |||
Nova Scotia | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes - EDS | Yes - EDS | |||
Nunavut | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | Yes – L/U | |||
Ontario | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | No | |||
Prince Edward Island | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes - S/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – S/A | Yes – S/A | |||
Saskatchewan | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – EDS | Yes – EDS | |||
Yukon | Biologics and Biosimilars | Ixekizumab | Taltz® | Yes – L/U | Yes – L/U |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00047545.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Call 1-877-219-8908 for information.
Brodalumab (IL17 Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Brodalumab is a biologic that targets the overactive immune system in psoriasis. Brodalumab works by preventing interleukin-17 from causing inflammation.
How Is It Used?
Brodalumab is an injectable medication that is administered subcutaneously.
For plaque psoriasis:
210 mg at weeks 0, 1, and 2, followed by 210 mg once every 2 weeks
What Are The Possible Side Effects?
The most common side effect of brodalumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of brodalumab, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on brodalumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on brodalumab.
Brodalumab should be avoided in patients with Crohn’s disease.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
What Medications Interact With This Treatment?
Some medications that may interact with brodalumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with brodalumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Brodalumab | Siliq™ | No | N/A | https://pdf.hres.ca/dpd_pm/00044076.PDF | https://pdf.hres.ca/dpd_pm/00051682.PDF | June 7, 2019 |
British Columbia | Biologics and Biosimilars | Brodalumab | Siliq™ | No | N/A | |||
Manitoba | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | |||
New Brunswick | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | ||||
Newfoundland and Labrador | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A | |||
NIHB | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | |||
Northwest Territories | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | |||
Nova Scotia | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | |||
Nunavut | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | |||
Ontario | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A | |||
Prince Edward Island | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes - S/A | N/A | |||
Quebec | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – S/A | N/A | |||
Saskatchewan | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – EDS | N/A | |||
Yukon | Biologics and Biosimilars | Brodalumab | Siliq™ | Yes – L/U | N/A |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00044076.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Call 1-844-852-6967 for information.
Secukinumab (IL17 Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Secukinumab is a biologic that targets the overactive immune system in psoriasis. Secukinumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Secukinumab is an injectable medication that is administered subcutaneously.
For plaque psoriasis:
300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks
For psoriatic arthritis:
For patients not treated previously by a biological agent – 150 mg (or 300 mg for some patients) once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks. For those with previous treatment with a biologic agent – 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
What Are The Possible Side Effects?
The most common side effect of secukinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of secukinumab, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on secukinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on secukinumab.
Secukinumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
What Medications Interact With This Treatment?
Some medications that may interact with secukinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with secukinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
British Columbia | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A | |||
Manitoba | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – EDS | Yes – EDS | |||
New Brunswick | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A | |||
NIHB | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes - L/U | Yes - L/U | |||
Northwest Territories | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes - L/U | Yes - L/U | |||
Nova Scotia | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – EDS | Yes - EDS | |||
Nunavut | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes - L/U | Yes - L/U | |||
Ontario | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – L/U | No | |||
Prince Edward Island | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A | |||
Quebec | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – S/A | Yes – S/A | |||
Saskatchewan | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes – EDS | Yes – EDS | |||
Yukon | Biologics and Biosimilars | Secukinumab | Cosentyx® | Yes - L/U | Yes - L/U |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00052362.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Bimekizumab (IL17 Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Bimekizumab works by inhibiting the inflammatory proteins known as IL-17A and IL-17F. These inflammatory proteins are present in increased levels in psoriasis and by inhibiting them, this medication can help to achieve skin clearance and improvement in psoriasis symptoms.
How Is It Used?
Bimekizumab is an injectable medication that is administered subcutaneously. Patients can self-inject at home.
Bimekizumab is approved for the treatment of psoriasis. The recommended dose is 320mg (given as 2 subcutaneous injections of 160mg each) every 4 weeks for the first 16 weeks and then every 8 weeks thereafter.
If you weigh more than 120 kg, your healthcare professional may decide to continue your injections every 4 weeks from week 16. Follow your doctor’s instructions for optimal dosing.
Bimekizumab is available as a pre-filled syringe or autoinjector.
What Are The Possible Side Effects?
The most common side effects of bimekizumab include an increased risk of upper respiratory tract infection. To obtain a comprehensive list of all known potential side effects of bimekizumab, talk to your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on bimekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is safe to receive while on bimekizumab.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
Bimekizumab is not recommended in patients with inflammatory bowel disease.
What Medications Interact With This Treatment?
For a complete list of medications that may interact with bimekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Bimekizumab | Bimzelx® | Yes - S/A | N/A | https://pdf.hres.ca/dpd_pm/00064702.PDF | https://pdf.hres.ca/dpd_pm/00064702.PDF | February 14, 2022 |
British Columbia | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes – S/A | Yes – S/A | https://pdf.hres.ca/dpd_pm/00064702.PDF | ||
Manitoba | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - EDS | N/A | |||
New Brunswick | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - S/A | No | |||
Newfoundland and Labrador | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | N/A | |||
NIHB | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - L/U | N/A | |||
Northwest Territories | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - L/U | N/A | |||
Nova Scotia | Biologics and Biosimilars | Bimekizumab | Bimzelx | No | s.o. | |||
Nunavut | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - L/U | N/A | |||
Ontario | Biologics and Biosimilars | Bimekizumab | Bimzelx® | Yes- L/U | N/A | |||
Prince Edward Island | Biologics and Biosimilars | Bimekizumab | Bimzelx® | Yes - S/A | N/A | |||
Quebec | Biologics and Biosimilars | Bimekizumab | Bimzelx® | Yes - S/A | N/A | |||
Saskatchewan | Biologics and Biosimilars | Bimekizumab | Bimzelx® | Yes – EDS | N/A | |||
Yukon | Biologics and Biosimilars | Bimekizumab | Bimzelx | Yes - L/U | N/A |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00064702.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
1-800-908-5555
www.UCBCares.ca
Ustekinumab (IL12/23 Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Ustekinumab is a biologic that targets the overactive immune system in psoriasis. Ustekinumab works by suppressing interleukin 12 and interleukin 23. Useful for psoriasis and psoriatic arthritis.
How Is It Used?
Ustekinumab is an injectable medication that is administered subcutaneously. Can be home dosed.
For plaque psoriasis:
≤100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter
>100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter
For psoriatic arthritis:
45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.
What Are The Possible Side Effects?
The most common side effect of ustekinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ustekinumab, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on ustekinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ustekinumab.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
What Medications Interact With This Treatment?
Some medications that may interact with ustekinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ustekinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | N/A | https://pdf.hres.ca/dpd_pm/00048246.PDF | https://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/stelara_cpm.pdf | January 5, 2023 |
British Columbia | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | No | |||
Manitoba | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – EDS | No | |||
New Brunswick | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | No | |||
Newfoundland and Labrador | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | No | |||
NIHB | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No | |||
Northwest Territories | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No | |||
Nova Scotia | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes - EDS | No | |||
Nunavut | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No | |||
Ontario | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No | |||
Prince Edward Island | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes-S/A | No | |||
Quebec | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – S/A | Yes – S/A | |||
Saskatchewan | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – EDS | Yes – EDS | |||
Yukon | Biologics and Biosimilars | Ustekinumab | Stelara® | Yes – L/U | No |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00048246.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Risankizumab (IL23 Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Risankizumab is a biologic that targets the overactive immune system in psoriasis. Risankizumab works by supressing interleukin-23A.
How Is It Used?
The recommended dose of SKYRIZI is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
What Are The Possible Side Effects?
The most common side effect of risankizumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of risankizumab, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on risankizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on risankizumab.
Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.
What Medications Interact With This Treatment?
N/A
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Risankizumab | Skyrizi® | Yes – S/A | N/A | https://pdf.hres.ca/dpd_pm/00069300.PDF | ||
British Columbia | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A | |||
Manitoba | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – EDS | N/A | |||
New Brunswick | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A | |||
NIHB | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A | |||
Northwest Territories | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A | |||
Nova Scotia | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – EDS | N/A | |||
Nunavut | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A | |||
Ontario | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A | |||
Prince Edward Island | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A | |||
Quebec | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – S/A | N/A | |||
Saskatchewan | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – EDS | N/A | |||
Yukon | Biologics and Biosimilars | Risankizumab | Skyrizi™ | Yes – L/U | N/A |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00050697.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Guselkumab (IL23 Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
Guselkumab is a biologic that targets the overactive immune system in psoriasis. Guselkumab works by neutralizing interleukin-23.
How Is It Used?
Guselkumab is an injectable medication that is administered subcutaneously by injection. Guselkumab can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) such as methotrexate.
For plaque psoriasis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter
For psoriatic arthritis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter
The most common side effect of guselkumab is an increased risk of respiratory tract infections. To obtain a comprehensive list of all known potential side effects of guselkumab, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on guselkumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on guselkumab.
Patients should be screened for tuberculosis and infections prior to treatment.
Do not use TREMFYA®/TREMFYA One-Press™ if you are allergic to guselkumab or any of the ingredients in TREMFYA®/TREMFYA OnePress™.
If you think you are allergic, ask your healthcare professional for advice before using TREMFYA®/TREMFYA One-Press™.
What Medications Interact With This Treatment?
For a complete list of medications that may interact with guselkumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | https://pdf.hres.ca/dpd_pm/00057930.PDF | https://pdf.hres.ca/dpd_pm/00068091.PDF | November 8, 2022 |
British Columbia | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
Manitoba | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
New Brunswick | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
Newfoundland and Labrador | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
NIHB | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
Northwest Territories | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
Nova Scotia | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
Nunavut | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
Ontario | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
Prince Edward Island | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
Quebec | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
Saskatchewan | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No | |||
Yukon | Biologics and Biosimilars | Guselkumab | Tremfya® | No | No |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Health Canada Product Monograph
https://pdf.hres.ca/dpd_pm/00057930.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Abatacept
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
How Does It Work?
Abatacept is a biologic that targets the overactive immune system in psoriatic arthritis. Abatacept works by supressing the activation of white blood cells called T-cells.
How Is It Used?
Abatacept is a biologic medication that can be administered either subcutaneously or intravenously.
What Are The Possible Side Effects?
The most common side effects of abatacept are headache, nausea, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of abatacept, talk your doctor or pharmacist.
Any Other Important Considerations?
Some vaccinations, known as live vaccinations, should be avoided while on abatacept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on abatacept.
Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of experience COPD-related adverse events such as cough, shortness of breath, and infection while on abatacept.
Abatacept should be avoided in patients who are immunocompromised or HIV positive.
What Medications Interact With This Treatment?
Some medications that may interact with abatacept include anakinra, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, baricitinib, belimumab, cladribine, echinacea, leflunomide, natalizumab, pimecrolimus, rituximab, roflumilast, tacrolimus, tocilizumab, and tofacitinib. For a complete list of medications that may interact with abatacept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | https://pdf.hres.ca/dpd_pm/00045017.PDF | https://pdf.hres.ca/dpd_pm/00066773.PDF | July 21, 2022 |
British Columbia | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
Manitoba | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
New Brunswick | Biologics and Biosimilars | Abatacept | Orencia® | No | No | |||
Newfoundland and Labrador | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
NIHB | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
Northwest Territories | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
Nova Scotia | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
Nunavut | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
Ontario | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
Prince Edward Island | Biologics and Biosimilars | Abatacept | Orencia® | N/A | Yes - S/A | |||
Quebec | Biologics and Biosimilars | Abatacept | Orencia® | N/A | Yes - S/A | |||
Saskatchewan | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No | |||
Yukon | Biologics and Biosimilars | Abatacept | Orencia® | N/A | No |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00045017.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Tildrakizumab
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
How Does It Work?
Ilumya™ acts on specific molecular signals used by the immune system to decrease the immune system’s overactivity that can contribute to plaque psoriasis.
How Is It Used?
Ilumya™ is a drug taken by injection often in 12-week intervals.
What Are The Possible Side Effects?
Side effects of Ilumya™ can include diarrhea, skin irritation and muscle pain at the injection site, fatigue, increased risk of infection, joint pain, and headaches. To obtain a comprehensive list of all potential side effects, talk to your doctor or pharmacist.
Any Other Important Considerations?
Not applicable
What Medications Interact With This Treatment?
Certain vaccines cannot be taken while on Ilumya™. Talk to your doctor before being vaccinated to confirm it is safe to do so while on Ilumya. Ilumya may also interact with dextromethorphan. Ask your doctor or pharmacist if you are concerned about a drug interaction.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
---|---|---|---|---|---|---|---|---|
Alberta | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - SA | N/A | https://pdf.hres.ca/dpd_pm/00060995.PDF | https://pdf.hres.ca/dpd_pm/00064464.PDF | January 24, 2022 |
British Columbia | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A | |||
Manitoba | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - EDS | N/A | |||
New Brunswick | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - S/A | N/A | |||
Newfoundland and Labrador | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes – S/A | N/A | |||
NIHB | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - L/U | N/A | |||
Northwest Territories | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - L/U | N/A | |||
Nova Scotia | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes – EDS | N/A | |||
Nunavut | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - L/U | N/A | |||
Ontario | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes – L/U | N/A | |||
Prince Edward Island | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes-S/A | N/A | |||
Quebec | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | No | N/A | |||
Saskatchewan | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes – EDS | N/A | |||
Yukon | Biologics and Biosimilars | Tildrakizumab | Ilumya™ | Yes - L/U | N/A |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00060995.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
SPEVIGO® (IL 36 Blocker)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
- Patient Support Program
How Does It Work?
SPEVIGO (spesolimab for injection) inhibits the inflammatory signaling pathway of interleukin 36 (IL-36), and is indicated for the treatment of flares in adult patients with generalized pustular psoriasis (GPP).
How Is It Used?
Treatment with SPEVIGO (spesolimab for injection) should be initiated by physicians experienced in the management of patients with inflammatory skin diseases.
The recommended dose of SPEVIGO (spesolimab for injection) is a single dose of 900 mg (2 x 450 mg/7.5 ml vials) administered as an intravenous infusion. If flare symptoms persist, an additional 900 mg dose may be administered 1 week after the initial dose.
What Are The Possible Side Effects?
The most common side effects of SPEVIGO (spesolimab for injection) include fatigue/weakness, nausea and vomiting, headache, itching or itchy bumps, a collection of blood under the skin at the infusion site or bruising, and urinary tract infection. To obtain a comprehensive list of all known potential side effects of roflumilast, talk to your doctor or pharmacist.
Any Other Important Considerations?
SPEVIGO (spesolimab for injection) is contraindicated in patients with severe or life-threatening hypersensitivity to this drug or to any ingredients in the formulation, including any non-medicinal ingredients, or components of the container.
What Medications Interact With This Treatment?
No formal drug-drug interaction studies were conducted with SPEVIGO (spesolimab for injection). For a complete list of medications that may interact with SPEVIGO (spesolimab for injection) and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis | Current Monograph | Updated Monograph | Date of Revision: |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102523
https://pdf.hres.ca/dpd_pm/00070263.PDF
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Patient Support Program
headstartGO@supportprogram.com
Call toll-free: 1-833-773-4746
MedInfo can be accessed by health care providers for possible inquiries (1-800-263-5103 x84643, zrburmedinfo@boehringer-ingelheim.com).
Last updated October, 2022